{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T06:50:39Z","timestamp":1770274239820,"version":"3.49.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Placenta-derived mesenchymal cells (PLCs) endogenously produce FVIII, which makes them ideally suited for cell-based fVIII gene delivery. We have previously reported that human PLCs can be efficiently modified with a lentiviral vector encoding a bioengineered, expression\/secretion-optimized fVIII transgene (ET3) and durably produce clinically relevant levels of functionally active FVIII. The objective of the present study was to investigate whether CRISPR\/Cas9 can be used to achieve location-specific insertion of a fVIII transgene into a genomic safe harbor, thereby eliminating the potential risks arising from the semi-random genomic integration   inherent to lentiviral vectors. We hypothesized this approach would improve the safety of the PLC-based gene delivery platform and might also enhance the therapeutic effect by eliminating chromatin-related transgene silencing.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We used CRISPR\/Cas9 to attempt to insert the bioengineered fVIII transgene \u201clcoET3\u201d into the AAVS1 site of PLCs (CRISPR-lcoET3) and determined their subsequent levels of FVIII production, comparing results with this approach to those achieved using lentivector transduction (LV-lcoET3) and plasmid transfection (Plasmid-lcoET3). In addition, since liver-derived sinusoidal endothelial cells (LSECs) are the native site of FVIII production in the body, we also performed parallel studies in human (h)LSECs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>PLCs and hLSECs can both be transduced (LV-lcoET3) with very high efficiency and produce high levels of biologically active FVIII. Surprisingly, both cell types were largely refractory to CRISPR\/Cas9-mediated knockin of the lcoET3 fVIII transgene in the AAVS1 genome locus. However, successful insertion of an RFP reporter into this locus using an identical procedure suggests the failure to achieve knockin of the lcoET3 expression cassette at this site is likely a function of its large size. Importantly, using plasmids, alone or to introduce the CRISPR\/Cas9 \u201cmachinery\u201d, resulted in dramatic upregulation of TLR 3, TLR 7, and BiP in PLCs, compromising their unique immune-inertness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Although we did not achieve our primary objective, our results validate the utility of both PLCs and hLSECs as cell-based delivery vehicles for a fVIII transgene, and they highlight the hurdles that remain to be overcome before primary human cells can be gene-edited with sufficient efficiency for use in cell-based gene therapy to treat HA.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.954984","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T08:18:24Z","timestamp":1671092304000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of different gene addition strategies to modify placental derived-mesenchymal stromal cells to produce FVIII"],"prefix":"10.3389","volume":"13","author":[{"given":"Ritu M.","family":"Ramamurthy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah C.","family":"Ainsworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan","family":"Shields","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Meares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Farland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl D.","family":"Langefeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Atala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher B.","family":"Doering","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Trent","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher D.","family":"Porada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gra\u00e7a","family":"Almeida-Porada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,12,15]]},"reference":[{"key":"B1","volume-title":"Hemophilia","author":"Mehta","year":"2021"},{"key":"B2","unstructured":"Hemophilia a - an overview of symptoms, genetics, and treatments to help you understand hemophilia a. 2022"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.678117","article-title":"Investigating optimal autologous cellular platforms for prenatal or perinatal factor VIII delivery to treat hemophilia a","volume":"9","author":"Stem","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2015.1016228","article-title":"Economic costs of hemophilia and the impact of prophylactic treatment on patient management","volume":"22","author":"Chen","year":"2016","journal-title":"Am J Manag Care"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abg0856","article-title":"Hemophilia as a blueprint for gene therapy","volume":"374","author":"Ragni","year":"2021","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.221093","article-title":"Hemophilia a and b: Molecular and clinical similarities and differences","volume":"104","author":"Castaman","year":"2019","journal-title":"Haematologica"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.13605","article-title":"Gene therapy for hemophilia: Current status and laboratory consequences","author":"Batty","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2014.2541","article-title":"Gene therapy for hemophilia: The clot thickens","volume":"25","author":"High","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1182\/blood-2018-99-115495","article-title":"A phase I\/II trial of investigational spk-8011 in hemophilia a demonstrates durable expression and prevention of bleeds","volume":"132","author":"High","year":"2018","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104205","article-title":"Multiyear factor VIII expression after AAV gene transfer for hemophilia a","volume":"385","author":"George","year":"2021","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for hemophilia a","volume":"382","author":"Pasi","year":"2020","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005683","article-title":"Activity of transgene-produced b-domain-deleted factor VIII in human plasma following AAV5 gene therapy","volume":"136","author":"Rosen","year":"2020","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"4916a","DOI":"10.1182\/blood-2021-146021","article-title":"Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia a in the phase 3 trial GENEr8-1","volume":"138","author":"O'Mahony","year":"2021","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.138","article-title":"Adeno-associated virus-based gene therapy for lifelong correction of genetic disease","volume":"31","author":"Brommel","year":"2020","journal-title":"Hum Gene Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3233\/JND-210683","article-title":"Changes in myonuclear number during postnatal growth - implications for AAV gene therapy for muscular dystrophy","volume":"8","author":"Morgan","year":"2021","journal-title":"J Neuromuscul Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00276","article-title":"Hemophilia a: An ideal disease to correct in utero","volume":"5","author":"Porada","year":"2014","journal-title":"Front Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"16063","DOI":"10.1038\/mtm.2016.63","article-title":"Potential for cellular stress response to hepatic factor VIII expression from AAV vector","volume":"3","author":"Zolotukhin","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615018","article-title":"Post-translational modifications required for coagulation factor secretion and function","volume":"79","author":"Kaufman","year":"1998","journal-title":"Thromb Haemost"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1331799","article-title":"Amniotic fluid and placental membranes: Unexpected sources of highly multipotent cells","volume":"31","author":"Murphy","year":"2013","journal-title":"Semin Reprod Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s13287-015-0140-z","article-title":"Human amniotic mesenchymal stromal cells (hAMSCs) as potential vehicles for drug delivery in cancer therapy: An in vitro study","volume":"6","author":"Bonomi","year":"2015","journal-title":"Stem Cell Res Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/0963689717742819","article-title":"The immunomodulatory properties of amniotic cells: The two sides of the coin","volume":"27","author":"Magatti","year":"2018","journal-title":"Cell Transplant"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.03.001","article-title":"Defining the optimal FVIII transgene for placental cell-based gene therapy to treat hemophilia a","volume":"17","author":"El-Akabawy","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI1250","article-title":"Intracellular trafficking of factor VIII to von willebrand factor storage granules","volume":"101","author":"Rosenberg","year":"1998","journal-title":"J Clin Invest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-272419","article-title":"Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia a","volume":"116","author":"Shi","year":"2010","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1365-2516.2009.02005.x","article-title":"Factor VIII and von willebrand factor interaction: Biological, clinical and therapeutic importance","volume":"16","author":"Terraube","year":"2010","journal-title":"Haemophilia"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01575.x","article-title":"Factor VIII inhibitors: Role of von willebrand factor on the uptake of factor VIII by dendritic cells","author":"Kaveri","year":"2007","journal-title":"Haemophilia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(08)70002-1","article-title":"The role of VWF in the immunogenicity of FVIII","author":"Lacroix-Desmazes","year":"2008","journal-title":"Thromb Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01460.x","article-title":"Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients","volume":"3","author":"High","year":"2005","journal-title":"J Thromb Haemost"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1055\/s-2003-37945","article-title":"Gene transfer as an approach to treating hemophilia","volume":"29","author":"High","year":"2003","journal-title":"Semin Thromb Hemost"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1538-7836.2011.04369.x","article-title":"Gene therapy for haemophilia: a long and winding road","author":"High","year":"2011","journal-title":"J Thromb Haemost"},{"key":"B31","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.omtm.2018.01.004","article-title":"Target-Cell-Directed bioengineering approaches for gene therapy of hemophilia a","volume":"9","author":"Brown","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.238758","article-title":"Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response","volume":"286","author":"Brown","year":"2011","journal-title":"J Biol Chem"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.35","article-title":"Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia a","volume":"17","author":"Doering","year":"2009","journal-title":"Mol Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M312451200","article-title":"Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion","volume":"279","author":"Doering","year":"2004","journal-title":"J Biol Chem"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3677","article-title":"Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction","volume":"35","author":"Zakas","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1089\/hum.1998.9.3-353","article-title":"Bone marrow stromal cells as targets for gene therapy of hemophilia a","volume":"9","author":"Chuah","year":"1998","journal-title":"Hum Gene Ther"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1089\/10430340050015626","article-title":"Long-term persistence of human bone marrow stromal cells transduced with factor VIII-retroviral vectors and transient production of therapeutic levels of human factor VIII in nonmyeloablated immunodeficient mice","volume":"11","author":"Chuah","year":"2000","journal-title":"Hum Gene Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-237-3_12","article-title":"Retroviral modification of mesenchymal stem cells for gene therapy of hemophilia","volume":"433","author":"Doering","year":"2008","journal-title":"Methods Mol Biol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300146","article-title":"Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia a mice with pre-existing factor VIII immunity","volume":"15","author":"Doering","year":"2007","journal-title":"Mol Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2008.150","article-title":"Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia a","volume":"20","author":"Dooriss","year":"2009","journal-title":"Hum Gene Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4961","article-title":"High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells","volume":"107","author":"Gangadharan","year":"2006","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-082602","article-title":"Hematopoietic stem-cell gene therapy of hemophilia a incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens","volume":"110","author":"Ide","year":"2007","journal-title":"Blood"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.1442","article-title":"Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia a","volume":"12","author":"Ide","year":"2010","journal-title":"J Gene Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.4172\/2157-7412.S1-003","article-title":"Engineered hematopoietic stem cells as therapeutics for hemophilia a","volume":"1","author":"Zakas","year":"2011","journal-title":"J Genet Syndr Gene Ther"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.137","article-title":"Preclinical development of a hematopoietic stem and progenitor cell bioengineered factor VIII lentiviral vector gene therapy for hemophilia a","volume":"29","author":"Doering","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2012.76","article-title":"Generation of an optimized lentiviral vector encoding a high-expression factor VIII transgene for gene therapy of hemophilia a","volume":"20","author":"Johnston","year":"2013","journal-title":"Gene Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.239","article-title":"Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII","volume":"19","author":"Spencer","year":"2011","journal-title":"Mol Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"14036","DOI":"10.1038\/mtm.2014.36","article-title":"Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia a following liver-directed adeno-associated viral vector delivery","volume":"1","author":"Brown","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.682","article-title":"Ten years of gene therapy for primary immune deficiencies","author":"Aiuti","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2008.93","article-title":"In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors","volume":"16","author":"Bauer","year":"2008","journal-title":"Mol Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01865-08","article-title":"Insertional gene activation by lentiviral and gammaretroviral vectors","volume":"83","author":"Bokhoven","year":"2009","journal-title":"J Virol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1172\/JCI35798","article-title":"Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients","volume":"118","author":"Howe","year":"2008","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.5966\/sctm.2013-0206","article-title":"Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases","volume":"3","author":"Williams","year":"2014","journal-title":"Stem Cells Transl Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkr409","article-title":"Efficient recombinase-mediated cassette exchange at the AAVS1 locus in human embryonic stem cells using baculoviral vectors","volume":"39","author":"Ramachandra","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/jth.12412","article-title":"Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII","volume":"12","author":"Shahani","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12750","article-title":"Progress and challenges in the development of a cell-based therapy for hemophilia a","volume":"12","author":"Fomin","year":"2014","journal-title":"J Thromb Haemost"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302364","article-title":"Immune responses to gene therapy vectors: influence on vector function and effector mechanisms","author":"Bessis","year":"2004","journal-title":"Gene Ther"},{"key":"B59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1517\/17425247.5.1.11","article-title":"Liposome-nucleic acid immunotherapeutics","volume":"5","author":"Dow","year":"2008","journal-title":"Expert Opin Drug Delivery"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1556\/EuJMI.1.2011.4.3","article-title":"Adenovirus-triggered innate signalling pathways","volume":"1","author":"Fejer","year":"2011","journal-title":"Eur J Microbiol Immunol (Bp)"},{"key":"B61","doi-asserted-by":"publisher","first-page":"14041","DOI":"10.1038\/mtm.2014.41","article-title":"Evaluation of gene delivery strategies to efficiently overexpress functional HLA-G on human bone marrow stromal cells","volume":"2014","author":"Boura","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B62","doi-asserted-by":"publisher","first-page":"16064","DOI":"10.1038\/mtm.2016.64","article-title":"Overexpression of factor VIII after AAV delivery is transiently associated with cellular stress in hemophilia a mice","volume":"3","author":"Lange","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0809677105","article-title":"Antioxidants reduce endoplasmic reticulum stress and improve protein secretion","volume":"105","author":"Malhotra","year":"2008","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B64","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1038\/s41467-020-16065-3","article-title":"Cas9-AAV6-engineered human mesenchymal stromal cells improved cutaneous wound healing in diabetic mice","volume":"11","author":"Srifa","year":"2020","journal-title":"Nat Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/7651_2021_422","article-title":"CRISPR\/Cas-mediated knock-in of genetically encoded fluorescent biosensors into the AAVS1 locus of human-induced pluripotent stem cells","volume":"2549","author":"Stellon","year":"2022","journal-title":"Methods Mol Biol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-0716-2301-5_6","article-title":"Targeting the AAVS1 site by CRISPR\/Cas9 with an inducible transgene cassette for the neuronal differentiation of human pluripotent stem cells","volume":"2495","author":"Gu","year":"2022","journal-title":"Methods Mol Biol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.15283\/ijsc18110","article-title":"CRISPR\/Cas9 edited sRAGE-MSCs protect neuronal death in parkinsons disease model","volume":"12","author":"Lee","year":"2019","journal-title":"Int J Stem Cells"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.639070","article-title":"Effects of shear stress on production of FVIII and vWF in a cell-based therapeutic for hemophilia a","volume":"9","author":"Trevisan","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s40778-019-00165-y","article-title":"Mechanistic insights into factor VIII immune tolerance induction via prenatal cell therapy in hemophilia a","volume":"5","author":"Rodriguez","year":"2019","journal-title":"Curr Stem Cell Rep"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia b","volume":"365","author":"Nathwani","year":"2011","journal-title":"N Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.06.025","article-title":"CRISPR-Cas9-Mediated In vivo gene integration at the albumin locus recovers hemostasis in neonatal and adult hemophilia b mice","volume":"18","author":"Wang","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.03.121","article-title":"Autologous and heterologous cell therapy for hemophilia b toward functional restoration of factor IX","volume":"23","author":"Ramaswamy","year":"2018","journal-title":"Cell Rep"},{"key":"B73","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13287-018-0839-8","article-title":"Targeted genome engineering in human induced pluripotent stem cells from patients with hemophilia b using the CRISPR-Cas9 system","volume":"9","author":"Lyu","year":"2018","journal-title":"Stem Cell Res Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2015.07.001","article-title":"Functional correction of Large factor VIII gene chromosomal inversions in hemophilia a patient-derived iPSCs using CRISPR-Cas9","volume":"17","author":"Park","year":"2015","journal-title":"Cell Stem Cell"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0243-1","article-title":"Restoration of FVIII expression by targeted gene insertion in the FVIII locus in hemophilia a patient-derived iPSCs","volume":"51","author":"Sung","year":"2019","journal-title":"Exp Mol Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.stemcr.2019.04.016","article-title":"Universal correction of blood coagulation factor VIII in patient-derived induced pluripotent stem cells using CRISPR\/Cas9","volume":"12","author":"Park","year":"2019","journal-title":"Stem Cell Rep"},{"key":"B77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13059-017-1164-8","article-title":"Efficient precise knockin with a double cut HDR donor after CRISPR\/Cas9-mediated double-stranded DNA cleavage","volume":"18","author":"Zhang","year":"2017","journal-title":"Genome Biol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1186\/s13059-019-1907-9","article-title":"Curing hemophilia a by NHEJ-mediated ectopic F8 insertion in the mouse","volume":"20","author":"Zhang","year":"2019","journal-title":"Genome Biol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"16838","DOI":"10.1038\/s41598-019-53198-y","article-title":"Hemophilia a ameliorated in mice by CRISPR-based in vivo genome editing of human factor VIII","volume":"9","author":"Chen","year":"2019","journal-title":"Sci Rep"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3591","article-title":"Bioengineering of coagulation factor VIII for improved secretion","volume":"103","author":"Miao","year":"2004","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0167","article-title":"Phase 1 trial of FVIII gene transfer for severe hemophilia a using a retroviral construct administered by peripheral intravenous infusion","volume":"102","author":"Powell","year":"2003","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","first-page":"110621","DOI":"10.1016\/j.celrep.2022.110621","article-title":"Therapeutic correction of hemophilia a by transplantation of hPSC-derived liver sinusoidal endothelial cell progenitors","volume":"39","author":"Gage","year":"2022","journal-title":"Cell Rep"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630353","article-title":"Restoration of FVIII function and phenotypic rescue in hemophilia a mice by transplantation of MSCs derived from F8-modified iPSCs","volume":"9","author":"Qiu","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"18865","DOI":"10.1038\/srep18865","article-title":"In situ genetic correction of F8 intron 22 inversion in hemophilia a patient-specific iPSCs","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep"},{"key":"B85","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3390\/ijms23020623","article-title":"Ectopic expression of FVIII in HPCs and MSCs derived from hiPSCs with site-specific integration of ITGA2B promoter-driven BDDF8 gene in hemophilia a","volume":"23","author":"Zhao","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B86","doi-asserted-by":"publisher","first-page":"121429","DOI":"10.1016\/j.biomaterials.2022.121429","article-title":"Therapeutic correction of hemophilia a using 2D endothelial cells and multicellular 3D organoids derived from CRISPR\/Cas9-engineered patient iPSCs","volume":"283","author":"Son","year":"2022","journal-title":"Biomaterials"},{"key":"B87","doi-asserted-by":"publisher","first-page":"101948","DOI":"10.1016\/j.scr.2020.101948","article-title":"Generation of a gene edited hemophilia a patient-derived iPSC cell line, YCMi001-B-1, by targeted insertion of coagulation factor FVIII using CRISPR\/Cas9","volume":"48","author":"Sung","year":"2020","journal-title":"Stem Cell Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.3390\/ijms21113747","article-title":"High homology-directed repair using mitosis phase and nucleus localizing signal","volume":"21","author":"Han","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B89","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1093\/jrr\/rraa095","article-title":"Mitotic cells can repair DNA double-strand breaks via a homology-directed pathway","volume":"62","author":"Sakamoto","year":"2021","journal-title":"J Radiat Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1089\/crispr.2021.0063","article-title":"CRISPR-cas gene perturbation and editing in human induced pluripotent stem cells","volume":"4","author":"van Essen","year":"2021","journal-title":"CRISPR J"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1177\/1535370220985808","article-title":"Convergence of human pluripotent stem cell, organoid, and genome editing technologies","volume":"246","author":"Wang","year":"2021","journal-title":"Exp Biol Med (Maywood)"},{"key":"B92","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1038\/s41467-018-04580-3","article-title":"In vivo base editing of post-mitotic sensory cells","volume":"9","author":"Yeh","year":"2018","journal-title":"Nat Commun"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-555151","article-title":"A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII","volume":"123","author":"Fahs","year":"2014","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/2211-5463.12867","article-title":"Extended in vitro culture of primary human mesenchymal stem cells downregulates Brca1-related genes and impairs DNA double-strand break recognition","volume":"10","author":"Bao","year":"2020","journal-title":"FEBS Open Bio"},{"key":"B95","doi-asserted-by":"publisher","first-page":"8270464","DOI":"10.1155\/2016\/8270464","article-title":"In vitro expansion of bone marrow derived mesenchymal stem cells alters DNA double strand break repair of etoposide induced DNA damage","volume":"2016","author":"Hare","year":"2016","journal-title":"Stem Cells Int 2016."},{"key":"B96","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s13287-019-1334-6","article-title":"Long-term culture of mesenchymal stem cells impairs ATM-dependent recognition of DNA breaks and increases genetic instability","volume":"10","author":"Hladik","year":"2019","journal-title":"Stem Cell Res Ther"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.954984\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T08:18:30Z","timestamp":1671092310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.954984\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,15]]},"references-count":96,"alternative-id":["10.3389\/fimmu.2022.954984"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.954984","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,15]]},"article-number":"954984"}}